Welcome to our dedicated page for Polypid news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid stock.
PolyPid Ltd. develops locally administered, controlled-release therapeutics based on its proprietary PLEX drug-delivery technology. The company’s lead product candidate, D-PLEX100, is designed for prevention of surgical site infections in abdominal colorectal surgery, and company updates commonly cover Phase 3 SHIELD II data, pharmacokinetics, FDA interactions, New Drug Application activity, and manufacturing-readiness topics.
PolyPid news also includes financial results, operational highlights, investor-conference participation, and broader pipeline references spanning surgical care, oncology, obesity, diabetes, and other metabolic-disease applications. Recurring disclosures focus on clinical and regulatory progress, product-candidate development, and the financing and business updates typical of a late-stage biopharmaceutical issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PolyPid Ltd. (Nasdaq: PYPD) announced that it will disclose its Q1 2023 financial results and operational highlights on May 10, 2023, before U.S. market opening. This marks a critical period as the company aims to enhance surgical outcomes with its innovative technology. A conference call is scheduled for 8:30 AM ET that day to discuss the results and future business updates.
PolyPid's lead product candidate, D-PLEX100, is undergoing Phase 3 trials targeting surgical site infections, while the company is also exploring OncoPLEX for treating solid tumors, starting with glioblastoma. Investors and analysts are eagerly awaiting insights that could influence stock performance.
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on enhancing surgical outcomes, announced its participation in several upcoming investor conferences. The events include:
- Aegis Capital Corp. Virtual Conference: May 3, 2023, at 10:30 AM ET
- Sidoti & Company Micro-Cap Virtual Conference: May 11, 2023, at 9:15 AM ET
- JMP Securities Life Sciences Conference: May 15, 2023, at 2:30 PM ET
During these conferences, PolyPid's management will engage in one-on-one investor meetings. The company aims to provide insights into its lead product candidate, D-PLEX100, currently in Phase 3 trials for preventing surgical site infections. Furthermore, PolyPid is exploring OncoPLEX for solid tumor treatments, including glioblastoma.